DK0892852T3 - Indkapslede celler, som udtrykker cytochrom-P450 til pro-drug-aktivering - Google Patents

Indkapslede celler, som udtrykker cytochrom-P450 til pro-drug-aktivering

Info

Publication number
DK0892852T3
DK0892852T3 DK97919307T DK97919307T DK0892852T3 DK 0892852 T3 DK0892852 T3 DK 0892852T3 DK 97919307 T DK97919307 T DK 97919307T DK 97919307 T DK97919307 T DK 97919307T DK 0892852 T3 DK0892852 T3 DK 0892852T3
Authority
DK
Denmark
Prior art keywords
pro
cells expressing
encapsulated cells
drug activation
cytochrome
Prior art date
Application number
DK97919307T
Other languages
Danish (da)
English (en)
Inventor
Walter H Guenzburg
Peter Karle
Robert Michael Saller
Original Assignee
Bavarian Nordic Res Inst As
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8092560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0892852(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic Res Inst As, Gsf Forschungszentrum Umwelt filed Critical Bavarian Nordic Res Inst As
Application granted granted Critical
Publication of DK0892852T3 publication Critical patent/DK0892852T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK97919307T 1996-03-27 1997-03-27 Indkapslede celler, som udtrykker cytochrom-P450 til pro-drug-aktivering DK0892852T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK35296 1996-03-27
EP97919307A EP0892852B1 (de) 1996-03-27 1997-03-27 Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe

Publications (1)

Publication Number Publication Date
DK0892852T3 true DK0892852T3 (da) 2006-03-06

Family

ID=8092560

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97919307T DK0892852T3 (da) 1996-03-27 1997-03-27 Indkapslede celler, som udtrykker cytochrom-P450 til pro-drug-aktivering

Country Status (19)

Country Link
US (1) US6893634B1 (de)
EP (1) EP0892852B1 (de)
JP (1) JP4229982B2 (de)
AT (1) ATE309383T1 (de)
AU (1) AU713382B2 (de)
CA (1) CA2250173A1 (de)
CZ (1) CZ288074B6 (de)
DE (1) DE69730595D1 (de)
DK (1) DK0892852T3 (de)
ES (1) ES2253775T3 (de)
HU (1) HU221349B1 (de)
IL (1) IL125795A0 (de)
NO (1) NO325392B1 (de)
NZ (1) NZ331765A (de)
PL (1) PL188323B1 (de)
RU (2) RU2223788C2 (de)
SI (1) SI0892852T1 (de)
SK (1) SK282744B6 (de)
WO (1) WO1997035994A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU708273B2 (en) 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
RU2223788C2 (ru) 1996-03-27 2004-02-20 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром p450 ретровирусные векторы
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
EP1115871A2 (de) * 1998-09-21 2001-07-18 Transgene S.A. Pharmazeutische zusammensetzung zur vorbehandlung eines droge- oder prodrogebedürftigen patienten
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
AU1869900A (en) * 1999-01-04 2000-07-24 Ml Laboratories Plc P450/acetaminophen GDEPT for cancer treatment
GB9900009D0 (en) * 1999-01-04 1999-02-24 Ml Lab Plc Gene therapy
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
EP1427836A2 (de) * 2001-09-21 2004-06-16 Oxford Biomedica (UK) Limited Pseudotyped retrovirales vektorsystem
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
MX2015006813A (es) * 2015-05-29 2016-11-28 Univ Nac Autónoma De México Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927089T2 (de) 1988-05-17 1997-04-03 Sloan Kettering Inst Cancer Retroviraler vektor
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
JP4037446B2 (ja) 1994-09-02 2008-01-23 ゲーエスエフ − フォルシュンクスツェントルム・フューア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 非自己不活化性の発現標的化レトロウイルスベクタ
AU708273B2 (en) 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
ES2174103T3 (es) * 1995-09-06 2002-11-01 Austrian Nordic Biotherapeutic Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
RU2223788C2 (ru) 1996-03-27 2004-02-20 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром p450 ретровирусные векторы

Also Published As

Publication number Publication date
NO984540L (no) 1998-09-28
EP0892852B1 (de) 2005-11-09
PL188323B1 (pl) 2005-01-31
PL329071A1 (en) 1999-03-15
NO984540D0 (no) 1998-09-28
CZ305098A3 (cs) 1999-01-13
HUP9904116A2 (hu) 2000-04-28
RU2185821C2 (ru) 2002-07-27
SI0892852T1 (sl) 2006-04-30
NZ331765A (en) 2000-02-28
ES2253775T3 (es) 2006-06-01
WO1997035994A2 (en) 1997-10-02
DE69730595D1 (de) 2004-10-14
HU221349B1 (en) 2002-09-28
CZ288074B6 (cs) 2001-04-11
JP2000509249A (ja) 2000-07-25
JP4229982B2 (ja) 2009-02-25
NO325392B1 (no) 2008-04-21
HUP9904116A3 (en) 2001-01-29
SK132398A3 (en) 1999-04-13
WO1997035994A3 (en) 1997-11-20
EP0892852A2 (de) 1999-01-27
US6893634B1 (en) 2005-05-17
AU713382B2 (en) 1999-12-02
ATE309383T1 (de) 2005-11-15
RU2223788C2 (ru) 2004-02-20
AU2382797A (en) 1997-10-17
IL125795A0 (en) 1999-04-11
SK282744B6 (sk) 2002-12-03
CA2250173A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
SE9801336D0 (sv) Enterala fluoxetin-piller
NO20020055L (no) Blanding egnet for a danne en myk kapsel, samt spiselig myk kapsel.
DK0892852T3 (da) Indkapslede celler, som udtrykker cytochrom-P450 til pro-drug-aktivering
AU1534699A (en) Osmotic dosage form comprising first and second coats
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
IL147220A0 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
AR016827A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
NO942835L (no) 1-benzensulfonyl-1,3-dihydro-2H-benzimidazol-2-on-derivater, fremstilling derav og farmasöytiske blandinger som inneholder dem
SE9704546D0 (sv) Novel compounds
HK1032958A1 (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments.
CA2294783A1 (fr) Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
DE3764595D1 (de) Herstellung einer gliedprothese und materialien, die dazu benoetigt werden.
AU6211501A (en) Dental care agents provided in the form of single-portion capsules
WO1991015512A3 (en) Hiv envelope polypeptides
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
DE3776620D1 (de) 3-propenylcephemderivate, ihre herstellung, zwischenverbindungen, pharmazeutische praeparate und anwendung.
DE60043442D1 (de) Ner aktiven phase und einer inaktiven phase
NO985571L (no) Legemiddel for autoimmunsykdommer
ES2139332T3 (es) Procedimiento para la preparacion del trihidrato del (2r,3s)-3-benzoilamino-2-hidroxi-3-fenilpropionato de 4,10-diacetoxi-2alfa-benzoiloxi-5beta,20-epoxi-1,7beta-dihidroxi-9-oxo-tax-11-en-13alfa-ilo.
IL134039A0 (en) Polyhydroxybutylpyrazines, their preparation and medicines containing them
WO2000017366A3 (en) Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
NO894516D0 (no) Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.